EA201301270A1 - Способ комбинированного, направленного к egfr лечения рака - Google Patents

Способ комбинированного, направленного к egfr лечения рака

Info

Publication number
EA201301270A1
EA201301270A1 EA201301270A EA201301270A EA201301270A1 EA 201301270 A1 EA201301270 A1 EA 201301270A1 EA 201301270 A EA201301270 A EA 201301270A EA 201301270 A EA201301270 A EA 201301270A EA 201301270 A1 EA201301270 A1 EA 201301270A1
Authority
EA
Eurasian Patent Office
Prior art keywords
once
treatment
weeks
egfr
administered
Prior art date
Application number
EA201301270A
Other languages
English (en)
Inventor
Луис Денис
Роберт Лоренс
Мехди Шахиди
Флавио Золька
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46085062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201301270(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201301270A1 publication Critical patent/EA201301270A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В заявке описан способ лечения пациентов, страдающих от рака, вызванного разрегуляцией рецептора эпидермального фактора роста человека (HER/EGFR человека), при этом необратимый ингибитор тирозинкиназы (TKI) вводят по непрерывной схеме, основанной на средней ежедневной суточной дозе в диапазоне от 10 до 50 мг, и mAB вводят совместно по схеме внутривенного введения (в/в) еженедельной средней дозы в диапазоне от 50 до 500 мг/м, повторяющейся три, два или один раз в неделю, один раз в две недели, один раз в три недели или по крайней мере один раз в месяц, пациенту, нуждающемуся в таком лечении.
EA201301270A 2011-05-17 2012-05-16 Способ комбинированного, направленного к egfr лечения рака EA201301270A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11166446 2011-05-17
PCT/EP2012/059098 WO2012156437A1 (en) 2011-05-17 2012-05-16 Method for egfr directed combination treatment of cancer

Publications (1)

Publication Number Publication Date
EA201301270A1 true EA201301270A1 (ru) 2014-05-30

Family

ID=46085062

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201301270A EA201301270A1 (ru) 2011-05-17 2012-05-16 Способ комбинированного, направленного к egfr лечения рака

Country Status (13)

Country Link
US (4) US8828391B2 (ru)
EP (1) EP2712320B1 (ru)
JP (2) JP6228111B2 (ru)
KR (1) KR20140031903A (ru)
CN (1) CN103533961B (ru)
AU (1) AU2012257727B2 (ru)
BR (1) BR112013029385A2 (ru)
CA (1) CA2836396A1 (ru)
CL (1) CL2013003133A1 (ru)
EA (1) EA201301270A1 (ru)
IL (1) IL228741A (ru)
MX (1) MX2013013018A (ru)
WO (1) WO2012156437A1 (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404697B2 (en) * 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
SI1948180T1 (sl) * 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
US10980879B2 (en) 2011-07-06 2021-04-20 Sykehuset Sørlandet Hf EGFR targeted therapy
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
JP6353788B2 (ja) 2012-01-13 2018-07-04 エイシア バイオサイエンシーズ インコーポレイテッド 抗がん剤としての複素環式化合物およびその使用
US9586965B2 (en) 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
JP2015527564A (ja) * 2012-06-07 2015-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 自己免疫抗体
WO2014095088A1 (en) 2012-12-21 2014-06-26 Sykehuset Sørlandet Hf Egfr targeted therapy of neurological disorders and pain
RU2677653C2 (ru) 2013-07-11 2019-01-18 Ацея Байосайенсиз Инк. Производные пиримидина в качестве ингибиторов киназы
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
WO2015112705A2 (en) * 2014-01-24 2015-07-30 Clovis Oncology, Inc. Therapeutic combinations for treating cancer
WO2015178946A1 (en) * 2014-04-04 2015-11-26 Biodesix, Inc. Treatment selection for lung cancer patients using mass spectrum of blood-based sample
CN104174031B (zh) * 2014-07-31 2017-06-13 清华大学 逆转肿瘤多药耐药的基因组合物‑h‑R3/PAMAM G5/GCS siRNA及其应用
CN104189920B (zh) * 2014-07-31 2017-02-01 清华大学 逆转肿瘤多药耐药的基因组合物h‑R3/PAMAM G5/MDR1 siRNA及其应用
WO2016090174A1 (en) * 2014-12-03 2016-06-09 Auckland Uniservices, Ltd. Kinase inhibitor prodrug for the treatment of cancer
US10982287B2 (en) 2015-01-06 2021-04-20 The Johns Hopkins University Response to EGFR blockade
EP3288963B1 (en) * 2015-05-01 2020-12-23 Wo, Andrew Man Chung Pink1 c-terminal domain polypeptide and methods using the same in cancer treatment
US20160333087A1 (en) * 2015-05-12 2016-11-17 Bioven 3 Limited Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US20190358320A1 (en) * 2015-05-12 2019-11-28 In3Bio Ltd. Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
US10533011B2 (en) 2015-10-09 2020-01-14 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
CN107684624A (zh) * 2016-08-05 2018-02-13 江苏嵌合体生物技术有限公司 表皮生长因子受体相关癌症的组合治疗
TWI808958B (zh) * 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
AU2017408099A1 (en) 2017-04-07 2019-11-07 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
WO2018234556A1 (en) * 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF PREVENTING OR TREATING CANCER RESISTANCE TO EGFR INHIBITION
MA50532A (fr) * 2017-11-03 2020-09-09 Univ Virginia Patent Foundation Compositions et méthodes pour le traitement de cancers
KR20200136417A (ko) * 2018-03-27 2020-12-07 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Her2 엑손 19 돌연변이를 보유하는 암 세포에 대해 항 종양 활성을 갖는 화합물
CN112423745A (zh) * 2018-06-25 2021-02-26 光谱制药有限公司 波齐替尼与抗-her1抗体、抗-her2抗体或抗-her4抗体的组合物及其使用方法
WO2020005932A1 (en) * 2018-06-25 2020-01-02 Spectrum Pharmaceuticals, Inc. Combination of poziotinib with cytotoxic agent and/or other molecularly targeted agent and use thereof
EP3599284A1 (en) 2018-07-27 2020-01-29 Bio-Id Diagnostic Inc. Simultaneous detection of multiple nucleic acid templates using modified primers
WO2020030977A2 (en) * 2018-08-07 2020-02-13 In3Bio Ltd. Methods and compositions for inhibition of egf/egfr pathway in cobination with anaplastic lymphoma kinase inhibitors
JP2022526159A (ja) * 2019-03-29 2022-05-23 アストラゼネカ・アクチエボラーグ 非小細胞肺がんの治療に使用するためのオシメルチニブ
WO2021142408A1 (en) 2020-01-11 2021-07-15 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Estrogen metabolite levels and cancer driver gene mutations in lung cancer risk stratification and treatment
AU2021396395A1 (en) * 2020-12-11 2023-07-27 Erasca, Inc. Combination therapies for the treatment of cancer
CN112300284B (zh) * 2020-12-29 2021-04-06 慈达(广州)生物技术有限公司 核酸筛选结合抗体检测用于癌症检测中的用途及其制备的试剂盒
CN113234832B (zh) * 2021-06-30 2022-06-03 深圳市狂风生命科技有限公司 人类egfr基因错义突变分子标志物及其在预测靶向抑制剂抗药性中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
EP1731511B1 (de) 1999-06-21 2015-08-12 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10063435A1 (de) 2000-12-20 2002-07-04 Boehringer Ingelheim Pharma Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
US20030225079A1 (en) 2002-05-11 2003-12-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy
DE10221018A1 (de) 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
DE10307165A1 (de) 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
SI1746999T1 (sl) 2004-05-06 2012-01-31 Warner Lambert Co 4-fenilamino-kinazolin-6-il-amidi
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
SI1948180T1 (sl) 2005-11-11 2013-06-28 Boehringer Ingelheim International Gmbh Kombinacijsko zdravljenje raka, ki obsega EGFR/HER2 inhibitorje
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
SI1981863T1 (sl) 2006-01-26 2013-01-31 Boehringer Ingelheim International Gmbh Postopek za pripravo aminokrotonilamino-substituiranih kinazolinskih derivatov
US8877764B2 (en) 2006-09-18 2014-11-04 Boehringer Ingelheim International Gmbh Method for treating cancer harboring EGFR mutations
CN104013956B (zh) * 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009030239A1 (en) * 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
UY31867A (es) 2008-06-06 2010-01-29 Boehringer Ingelheim Int Nuevas formulaciones farmacéuticas sólidas que comprenden bibw 2992
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
WO2010085845A1 (en) 2009-01-28 2010-08-05 The University Of Queensland Cancer therapy and/or diagnosis
KR101705158B1 (ko) * 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
ES2731901T3 (es) 2009-07-06 2019-11-19 Boehringer Ingelheim Int Proceso para el secado de BIBW2992, de sus sales y de formulaciones farmacéuticas sólidas que comprenden este ingrediente activo
JP5956342B2 (ja) * 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
KR101217526B1 (ko) 2010-06-11 2013-01-02 한미사이언스 주식회사 아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
CN103687597A (zh) * 2011-04-11 2014-03-26 艾伯维公司 用于治疗cipn的parp抑制剂

Also Published As

Publication number Publication date
EP2712320A1 (en) 2014-04-02
US20160101175A1 (en) 2016-04-14
KR20140031903A (ko) 2014-03-13
IL228741A0 (en) 2013-12-31
US8828391B2 (en) 2014-09-09
CA2836396A1 (en) 2012-11-22
JP6282296B2 (ja) 2018-02-21
WO2012156437A1 (en) 2012-11-22
EP2712320B1 (en) 2019-10-02
US20170312360A1 (en) 2017-11-02
JP2016065109A (ja) 2016-04-28
CL2013003133A1 (es) 2014-07-11
US20140341926A1 (en) 2014-11-20
CN103533961A (zh) 2014-01-22
IL228741A (en) 2016-08-31
JP2014513706A (ja) 2014-06-05
CN103533961B (zh) 2016-08-03
BR112013029385A2 (pt) 2017-01-31
MX2013013018A (es) 2014-01-31
NZ616183A (en) 2015-09-25
AU2012257727B2 (en) 2016-09-01
AU2012257727A1 (en) 2013-10-24
US20120294867A1 (en) 2012-11-22
JP6228111B2 (ja) 2017-11-08

Similar Documents

Publication Publication Date Title
EA201301270A1 (ru) Способ комбинированного, направленного к egfr лечения рака
MX2021001398A (es) Métodos y composiciones para la inhibición de la vía egf/egfr en combinación con inhibidores de la cinasa del linfoma anaplásico.
RU2013148721A (ru) Комбинации соединений, ингибирующих акт и вемурафениба и способы их применения
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
EA037351B8 (ru) Способ лечения злокачественных опухолей с использованием комбинации антител против pd-1 и ctla-4
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
PH12014501119A1 (en) Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
RU2015137596A (ru) Комбинация ингибитора EGFR T790М и ингибитора EGFR для лечения немелкоклеточного рака легкого
JP2012236857A5 (ru)
MX2021011110A (es) Tratamiento de ataque de angioedema hereditario con dosis reducida de anticuerpos que se unen a calicreína plasmática humana.
RU2014144254A (ru) Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение
WO2012079093A3 (en) Dosage and administration of bispecific scfv conjugates
NZ700924A (en) Dosage regimen for a pi-3 kinase inhibitor
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
JOP20200014A1 (ar) توليفة علاجية لمثبط كيناز تيروزين egfr من الجيل الثالث ومثبط raf
WO2016181225A3 (en) Methods and compositions for inhibition of egf/egfr pathway in combination with tyrosine kinase inhibitors
MX2012005497A (es) Tivozanib y temsirolimus en combinacion.
NZ602032A (en) Oral b12 therapy
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
RU2019108441A (ru) Режим дозирования
RU2021105387A (ru) Способы и композиции для подавления пути egf/egfr в комбинации с ингибиторами киназы анапластической лимфомы
Joerger et al. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
MA37930A1 (fr) Procédés pour le traitement du cancer utilisant le lipoplatine
Sanchez et al. Anti-Myeloma Effects of Carfilzomib with Cyclophosphamide (CY) or Bendamustine (Ben).
Farschtschi Hyoertension and proteinuria: 3 case reports